Trial reportScientific reports2026
An oral nutritional supplement with TRPM8 agonists as a cooling flavor improved swallowing function in post-stroke patients with oropharyngeal dysphagia.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Post-stroke patients with OD (PSOD) show impaired oropharyngeal sensory function, impaired safety during voluntary swallow (VS) and a critical reduction of spontaneous swallowing frequency (SSF), increasing the risk of aspiration of oropharyngeal secretions. Our aim was to evaluate the effect of oropharyngeal sensory stimulation on the VS and SSF in chronic PSOD patients using a cooling sensation flavoring (TRPM8 agonists) in an oral nutritional supplement (ONS) drink and comparing it with a control ONS. We performed a prospective, crossover, interventional and open-label clinical study on 50 PSOD patients. Patients were randomized into two groups, which differed from each other according to the order in which the ONS were administered: (1) Group A (n = 25): 1st visit, cooling sensation (active) + 2nd visit, control; and (2) Group B (n = 25): 1st visit, control + 2nd visit, active. The swallowing function was evaluated pre and post administration of each product using the volume-viscosity swallowing test (V-VST) for the VS, including the prevalence of impaired safety and efficacy, and SSF (swallows/minute). A saliva sample before and after the administration of control and active ONS' was collected to quantify substance P (SP) and calcitonin gen-related peptide (CGRP) by using ELISA. We observed that mean basal SSF in PSOD was low (0.29 ± 0.21 swallows/min). PSOD patients showed a significant increase in SSF (51.6%, p < 0.0001), a 22% (p = 0.0449) reduction in the prevalence of impaired safety during VS and a 15% (p = 0.0453) increase in the concentration of salivary SP after the administration of the active ONS. In contrast, no significant changes were observed after the administration of the control product. The order of administration did not affect the results. In conclusion, the TRPM8 compound included in the active ONS facilitates sensory perception, enhancing the peripheral release of SP and improving SSF and safety of swallow during VS in PSOD, which suggests both cortical, and brainstem enhancement of swallow responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.